ID: ALA154191

Max Phase: Preclinical

Molecular Formula: C10H11NO2S

Molecular Weight: 209.27

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)[C@@H]1CSC(c2ccccc2)N1

Standard InChI:  InChI=1S/C10H11NO2S/c12-10(13)8-6-14-9(11-8)7-4-2-1-3-5-7/h1-5,8-9,11H,6H2,(H,12,13)/t8-,9?/m0/s1

Standard InChI Key:  AZDYQBFYMBALBY-IENPIDJESA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 209.27

Molecular Weight (Monoisotopic): 209.0510

AlogP: 1.47

#Rotatable Bonds: 2

Polar Surface Area: 49.33

Molecular Species: ACID

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.90

CX Basic pKa: 6.63

CX LogP: -0.41

CX LogD: -1.14

Aromatic Rings: 1

Heavy Atoms: 14

QED Weighted: 0.77

Np Likeness Score: -0.06

References

1. Nagasawa HT, Goon DJ, Muldoon WP, Zera RT..  (1984)  2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of L-cysteine. Protection of mice against acetaminophen hepatotoxicity.,  27  (5): [PMID:6716397] [10.1021/jm00371a006]

2. Song ZC, Ma GY, Lv PC, Li HQ, Xiao ZP, Zhu HL..  (2009)  Synthesis, structure and structure-activity relationship analysis of 3-tert-butoxycarbonyl-2-arylthiazolidine-4-carboxylic acid derivatives as potential antibacterial agents.,  44  (10): [PMID:19423200] [10.1016/j.ejmech.2009.04.014]

3. Liu Y, Jing F, Xu Y, Xie Y, Shi F, Fang H, Li M, Xu W..  (2011)  Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors.,  19  (7): [PMID:21382719] [10.1016/j.bmc.2011.02.019]

4. Chen P, Horton LB, Mikulski RL, Deng L, Sundriyal S, Palzkill T, Song Y..  (2012)  2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases.,  22  (19): [PMID:22921080] [10.1016/j.bmcl.2012.08.012]

5. Önen Bayram FE, Sipahi H, Acar ET, Kahveci Ulugöl R, Buran K, Akgün H..  (2016)  The cysteine releasing pattern of some antioxidant thiazolidine-4-carboxylic acids.,  114  [PMID:27017266] [10.1016/j.ejmech.2016.03.019]

6. Hussein WM, Feder D, Schenk G, Guddat LW, McGeary RP..  (2018)  Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics.,  157  [PMID:30107365] [10.1016/j.ejmech.2018.08.004]

Source

Source(1):

• Scientific Literature